Various glomerular disease models associated with proteinuria have shown that increased urinary CD80 is closely related to patients with frequent recurrence of Minimal Change Nephropathy, and the current efficacy of CD80 inhibitors (abatacept) encourages further research on CD80 as a therapeutic target for patients with Minimal Change Nephropathy (42). This evidence concerns the gene CD80 and glomerular disorder.